NCT02463721

Brief Summary

Several studies have pointed out changes in the epidemiology of the causative bacteria in SBP and bacterascites and in their susceptibility to antibiotics. In particular, the development of beta-lactamase enzymes, which confer resistance to clavulanate, or extended spectrum beta-lactamases in Escherichia coli. The potential emergence of enterococci, methicillin-resistant S. aureus, or fluoroquinolone-resistant bacteria, following norfloxacin prophylaxis, is also a cause of concern since they may be associated with a higher risk of therapeutic failure. The microbial etiology of SBP remains relatively constant; however, the antibiotic resistance rate especially for third-generation cephalosporins (including cefotaxime and ceftazidime), ciprofloxacin, and ofloxacin increased dramatically

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2015

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2015

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

May 27, 2015

Completed
8 days until next milestone

First Posted

Study publicly available on registry

June 4, 2015

Completed
4.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2019

Completed
Last Updated

January 3, 2018

Status Verified

December 1, 2017

Enrollment Period

4.9 years

First QC Date

May 27, 2015

Last Update Submit

December 30, 2017

Conditions

Keywords

sbpculture

Outcome Measures

Primary Outcomes (1)

  • identification of SBP bacterial pathogens through gram stain or other specific stains

    identification of SBP bacterial pathogens through gram stain or other specific stains

    6 months

Study Arms (1)

SBP patients

OTHER

ascitic fluid culture and microbiological testing for 100 patients with liver cirrhosis and ascites with suspicion of SBP

Other: ascitic fluid culture and microbiological testing

Interventions

ascitic fluid culture and microbiological testing for 100 patients with liver cirrhosis and ascites with suspicion of SBP

SBP patients

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Liver cirrhosis with ascites and suspected to have SBP.
  • ascitic fluid PMNL ≥ 250 cells/mm3

You may not qualify if:

  • ascitic fluid with polymicrobial infections
  • patients started empirical antibiotics without prior culture.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tanta university hospital

Tanta, Egypt

RECRUITING

Study Officials

  • Sherief Abd-elsalam, lecturer

    hepatology dept-Tanta

    PRINCIPAL INVESTIGATOR
  • Sally Elnawasany, lecturer

    hepatology dept-Tanta

    STUDY CHAIR
  • WALAA eLKHALAWANY, lecturer

    hepatology dept-Tanta

    STUDY CHAIR

Central Study Contacts

Sherief Abd-elsalam, lecturer

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PI

Study Record Dates

First Submitted

May 27, 2015

First Posted

June 4, 2015

Study Start

January 1, 2015

Primary Completion

December 1, 2019

Study Completion

December 1, 2019

Last Updated

January 3, 2018

Record last verified: 2017-12

Locations